Status:
NOT_YET_RECRUITING
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Non-alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Steatohepatitis (NASH)
Eligibility:
All Genders
18-65 years
Brief Summary
Non-alcoholic fatty liver disease is a major health problem worldwide. It includes simple steatosis and NASH which has inflammation in the liver, with or without fibrosis. Fat content, fibrosis, and i...
Eligibility Criteria
Inclusion
- Between 18 and 65 years of age.
- Non-alcoholic fatty liver disease (NAFLD) patients at stage of either Non-alcoholic steatohepatitis (NASH) or simple steatosis
- NAFLD patients scheduled to undergo liver biopsy.
- No abnormal lesions detected at baseline MRI exam for healthy volunteers.
Exclusion
- Evidence of hepatocarcinoma (HCC) or any other types of neoplasm.
- Patients who had undergone liver transplantation.
- Any contraindications to either liver biopsy or MRI scan.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT05384652
Start Date
January 1 2024
End Date
June 30 2027
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong, Prince of Wale Hospital
Hong Kong, Shatin, Hong Kong